The US Food and Drug Administration (FDA) granted accelerated approval to Nuvalent's neladalkib (Nelkarmi) on November 17, expanding treatment options for adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC) who have received prior targeted therapy.
The approval applies to patients previously treated with alectinib as their only ALK tyrosine kinase inhibitor (TKI) in the unresectable locally advanced or metastatic setting, or those who have received at least 2 ALK TKIs and platinum-based chemotherapy.
The decision was supported by findings from the multicenter, single-arm, open-label ALKOVE-1 trial evaluating neladalkib in 222 patients across 2 previously treated populations.
Among 67 patients who received alectinib as their only prior ALK TKI, the confirmed overall response rate (ORR) was 49%. Among responders, 76% maintained their response for at least 6 months, and 52% maintained it for at least 12 months.
In a separate group of 155 patients previously treated with at least 2 ALK TKIs and platinum-based chemotherapy, the ORR was 32%. Among responders, 69% maintained their response for at least 6 months, and 51% maintained it for at least 12 months.
The FDA assessed confirmed ORRs and duration of response using RECIST version 1.1 criteria, with blinded independent central review. The trial did not include a randomized comparator group.
Neladalkib is administered orally at 150 mg once daily, with or without food, until disease progression or unacceptable toxicity.
Safety warnings include hepatotoxicity, renal toxicity, ocular toxicity, elevated creatine phosphokinase levels, and embryo-fetal toxicity. The most frequently reported adverse reactions, occurring in at least 20% of patients, included musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, fatigue, and hepatotoxicity.
The FDA granted the application priority review, along with breakthrough therapy and orphan drug designations.
Source: FDA
